Your browser doesn't support javascript.
loading
Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods.
Liebschutz, Jane M; Subramaniam, Geetha A; Stone, Rebecca; Appleton, Noa; Gelberg, Lillian; Lovejoy, Travis I; Bunting, Amanda M; Cleland, Charles M; Lasser, Karen E; Beers, Donna; Abrams, Catherine; McCormack, Jennifer; Potter, Gail E; Case, Ashley; Revoredo, Leslie; Jelstrom, Eve M; Kline, Margaret M; Wu, Li-Tzy; McNeely, Jennifer.
Afiliação
  • Liebschutz JM; Division of General Internal Medicine, Center for Research On Health Care, University of Pittsburgh, 200 Lothrop Street, Suite 933W, Pittsburgh, PA, 15213, USA. liebschutzjm@upmc.edu.
  • Subramaniam GA; National Institute On Drug Abuse, Bethesda, MD, USA.
  • Stone R; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
  • Appleton N; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
  • Gelberg L; David Geffen School of Medicine at UCLA, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
  • Lovejoy TI; Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA.
  • Bunting AM; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
  • Cleland CM; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
  • Lasser KE; Section of General Internal Medicine, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
  • Beers D; School of Public Health, Boston University, Boston, MA, USA.
  • Abrams C; Section of General Internal Medicine, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
  • McCormack J; Emory University School of Medicine, Atlanta, GA, USA.
  • Potter GE; The Emmes Company, LLC, Rockville, MD, USA.
  • Case A; The Emmes Company, LLC, Rockville, MD, USA.
  • Revoredo L; Biostatistics Research Branch, NIH/NIAID, Rockville, MD, USA.
  • Jelstrom EM; The Emmes Company, LLC, Rockville, MD, USA.
  • Kline MM; The Emmes Company, LLC, Rockville, MD, USA.
  • Wu LT; The Emmes Company, LLC, Rockville, MD, USA.
  • McNeely J; The Emmes Company, LLC, Rockville, MD, USA.
Addict Sci Clin Pract ; 18(1): 70, 2023 11 18.
Article em En | MEDLINE | ID: mdl-37980494
ABSTRACT

BACKGROUND:

Preventing progression to moderate or severe opioid use disorder (OUD) among people who exhibit risky opioid use behavior that does not meet criteria for treatment with opioid agonists or antagonists (subthreshold OUD) is poorly understood. The Subthreshold Opioid Use Disorder Prevention (STOP) Trial is designed to study the efficacy of a collaborative care intervention to reduce risky opioid use and to prevent progression to moderate or severe OUD in adult primary care patients with subthreshold OUD.

METHODS:

The STOP trial is a cluster randomized controlled trial, randomized at the PCP level, conducted in 5 distinct geographic sites. STOP tests the efficacy of the STOP intervention in comparison to enhanced usual care (EUC) in adult primary care patients with risky opioid use that does not meet criteria for moderate-severe OUD. The STOP intervention consists of (1) a practice-embedded nurse care manager (NCM) who provides patient participant education and supports primary care providers (PCPs) in engaging and monitoring patient-participants; (2) brief advice, delivered to patient participants by their PCP and/or prerecorded video message, about health risks of opioid misuse; and (3) up to 6 sessions of telephone health coaching to motivate and support behavior change. EUC consists of primary care treatment as usual, plus printed overdose prevention educational materials and an educational video on cancer screening. The primary outcome measure is self-reported number of days of risky (illicit or nonmedical) opioid use over 180 days, assessed monthly via text message using items from the Addiction Severity Index and the Current Opioid Misuse Measure. Secondary outcomes assess other substance use, mental health, quality of life, and healthcare utilization as well as PCP prescribing and monitoring behaviors. A mixed effects negative binomial model with a log link will be fit to estimate the difference in means between treatment and control groups using an intent-to-treat population.

DISCUSSION:

Given a growing interest in interventions for the management of patients with risky opioid use, and the need for primary care-based interventions, this study potentially offers a blueprint for a feasible and effective approach to improving outcomes in this population. TRIAL REGISTRATION Clinicaltrials.gov, identifier NCT04218201, January 6, 2020.
Assuntos
Palavras-chave

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Analgésicos Opioides / Transtornos Relacionados ao Uso de Opioides Limite: Adult / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Analgésicos Opioides / Transtornos Relacionados ao Uso de Opioides Limite: Adult / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article